JP2017505809A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505809A5
JP2017505809A5 JP2016563894A JP2016563894A JP2017505809A5 JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5 JP 2016563894 A JP2016563894 A JP 2016563894A JP 2016563894 A JP2016563894 A JP 2016563894A JP 2017505809 A5 JP2017505809 A5 JP 2017505809A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hepe
free acid
weight
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016563894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505809A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011054 external-priority patent/WO2015106215A2/en
Publication of JP2017505809A publication Critical patent/JP2017505809A/ja
Publication of JP2017505809A5 publication Critical patent/JP2017505809A5/ja
Ceased legal-status Critical Current

Links

JP2016563894A 2014-01-10 2015-01-12 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法 Ceased JP2017505809A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10
US61/926,052 2014-01-10
PCT/US2015/011054 WO2015106215A2 (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149177A Division JP2020002150A (ja) 2014-01-10 2019-08-15 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法

Publications (2)

Publication Number Publication Date
JP2017505809A JP2017505809A (ja) 2017-02-23
JP2017505809A5 true JP2017505809A5 (enExample) 2019-02-14

Family

ID=53520398

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016563894A Ceased JP2017505809A (ja) 2014-01-10 2015-01-12 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
JP2019149177A Pending JP2020002150A (ja) 2014-01-10 2019-08-15 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019149177A Pending JP2020002150A (ja) 2014-01-10 2019-08-15 15−hepeを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法

Country Status (15)

Country Link
US (2) US20150196521A1 (enExample)
EP (1) EP3091959A4 (enExample)
JP (2) JP2017505809A (enExample)
KR (1) KR20160132372A (enExample)
CN (1) CN106029051A (enExample)
AU (1) AU2015204531B2 (enExample)
BR (1) BR112016015997A2 (enExample)
CA (1) CA2935986A1 (enExample)
IL (1) IL246623A0 (enExample)
MX (1) MX2016008953A (enExample)
PH (1) PH12016501371A1 (enExample)
RU (2) RU2685706C2 (enExample)
SG (2) SG11201605601UA (enExample)
WO (1) WO2015106215A2 (enExample)
ZA (1) ZA201605492B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
JP2016538288A (ja) 2013-11-15 2016-12-08 ディグニティ サイエンシス リミテッド 多価不飽和ヒドロキシ脂肪酸の薬学的に許容される塩
US20180008567A1 (en) * 2015-01-16 2018-01-11 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
ES2851525T3 (es) * 2015-07-21 2021-09-07 Afimmune Ltd Composiciones que comprenden 15(S)-HEPE para su uso en la sensibilización de las células cancerosas a la radioterapia
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
CA3129008A1 (en) * 2015-12-18 2017-06-22 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1863476B1 (en) * 2005-03-16 2016-02-03 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ3系脂肪酸由来の新規抗炎症性代謝物
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Similar Documents

Publication Publication Date Title
JP2017505809A5 (enExample)
JP2016511753A5 (enExample)
JP2015078230A5 (enExample)
JP2014507446A5 (enExample)
JP2014515013A5 (enExample)
JP2017509667A5 (enExample)
JP2017537066A5 (enExample)
HRP20192299T1 (hr) Liječenje nafld i nash
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2013519675A5 (enExample)
JP2017513836A5 (enExample)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
JP2014221779A5 (enExample)
JP2014218522A5 (enExample)
JP2013520405A5 (enExample)
JP2015510916A5 (enExample)
JP2015155440A5 (enExample)
JP2017222722A5 (enExample)
JP2018538273A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
JP2016540015A5 (enExample)
JP2016530291A5 (enExample)
JP2016532632A5 (enExample)
JP2017518982A5 (enExample)